The economic impact of therapeutic noncompliance in chronic diseases has rarely been examined following qualitative standards for economic evaluation. This study illustrates the potential impact of noncompliance on the cost-utility of chronic treatments using the case of renal transplantation versus haemodialysis and examines the economic scope for compliance enhancing interventions. METHODS: Long term cost and outcomes in compliant and noncompliant renal transplant patients were simulated in a Markov model. The cost and outcome data that were imputed in the model were derived from a prospective study in renal transplantation candidates. Probabilities of adverse events, graft rejection, graft loss and death, in compliant and noncompliant renal transplant patients were derived from literature. A societal viewpoint was taken. RESULTS: Compared with dialysis, renal transplantation offers a better outcome in both compliant and non-compliant patients. Lifetime costs after transplantation in the compliant patient group are higher than lifetime dialysis costs and than life-time costs in the non-compliant patient group, mainly because compliant patients live longer after transplantation. Long-term outcomes after transplantation are better for compliant than for non-compliant patients. The mean cost per quality-adjusted life-year gained (QALY) in compliant patients relative to non-compliant patients is €36,606.94/QALY (95% confidence interval [35,157.13-37,986.57]). CONCLUSIONS
OBJECTIVES:
The Health Technology Assessment (HTA) Committee of the Philippine Health Insurance Corporation (PhilHealth) was established in 1999 to develop reimbursement policies on medical claims based on the cost-effectiveness of tests and treatments. ME-THODS: The most commonly prescribed drugs that PhilHealth does not reimburse are subjected to this assessment Because randomized controlled trials provide the best evidence of efficacy and effectiveness, only systematic reviews of RCTs and individuals RCTs are included.
The intervention in the study should have at least the drug being evaluated in one arm and a standard treatment in the other arm. Electronic search is done through the Internet in the MEDLINE by two independent searchers. Electronic search is also done in the CD version of the Cochrane Library Two independent reviewers review all abstracts and articles for possible inclusion. The full texts of the selected abstracts are retrieved at a library network. Two reviewers using a standard assessment form independently assess the validity and applicability of the included systematic reviews and clinical trials. Qualitative and if appropriate, quantitative methods are used to analyze and/or combine the results of the different studies in order to come up with a summary measure of effectiveness. RESULTS: Safety and cost-effectiveness data are obtained from the results of clinical trials, postmarketing surveillance studies, ADR reports from local and international sources and local retail drug costs. CONCLUSIONS: If the drug is less cost-effective or safe than the standard drug, then it is not recommended for inclusion in the PhilHealth positive list of reimbursable drugs. If the drug is more cost-effective and poses no additional risk compared with the standard drug, then the drug is recommended for inclusion in the positive list provided that it is used for the conditions for which it was found effective. [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] , IMS [1991 -1994 ] and Statistics Finland [1995 -2002 ) were combined to reliable price indices that reflect the development of drug prices in general and in different reimbursement categories. Two different index clusters (1980 = 100 and 1990 = 100) were produced. The latter enables more precise classification of different reimbursement categories. After constructing the nominal indices, real price indices were produced by adjusting nominal indices with Consumer Price Index (CPI, Statistics Finland) and its sub-index Consumer Price Index for Health Care (CPI-H, Statistics Finland). RESULTS: In 2002 the index (1980 = 100) for all drugs was 168 (CPI
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